^
Association details:
| Biomarker: | BAP1 mutation |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab.
Published date:
05/25/2023
Excerpt:
PFS-2 was significantly inferior for ccRCC patients with somatic BAP1 mutation treated with IO-based therapy.
DOI:
10.1200/JCO.2023.41.16_suppl.4545
